January 1, 2017Thrombosis and Haemostasis
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial
View Full Paper
Ask AI
Bookmark
Share
Key result
No clinical study data is present in the provided text, which consists only of the journal's editorial board and masthead information.
Why the study?
Does extended-duration betrixaban reduce the occurrence of deep vein thrombosis and thrombus burden in acutely ill hospitalized medical patients compared to enoxaparin?
Population
7,513 acutely ill hospitalized medical patients
Comparison
Extended-duration betrixaban (35–42 days) vs Enoxaparin (10 ± 4 days)
Design
RCT, randomly assigned
Follow-up
35 to 42 days
Authors
Discussion
Loading...
Member takes
Implication
No data to inform decisions; leaves open all questions on thrombosis and haemostasis.
Structured PICO
Does extended-duration betrixaban reduce the occurrence of deep vein thrombosis and thrombus burden in acutely ill hospitalized medical patients compared to enoxaparin?
P
Population
7,513 acutely ill hospitalized medical patients
I
Intervention
Extended-duration betrixaban (35–42 days)
C
Comparator
Enoxaparin (10 ± 4 days)
O
Outcome
Occurrence of deep vein thrombosis (DVT) and thrombus burden (assessed by the number of non-compressible vascular segments in six target proximal veins on mandatory lower-extremity compression ultrasonography) at 35 to 42 dayssurrogate
Extended-duration betrixaban reduces the risk of deep vein thrombosis and thrombus burden compared to standard-duration enoxaparin in acutely ill hospitalized medical patients.
Cite This Study
Chi et al. (2017) studied this question. No clinical study data is present in the provided text, which consists only of the journal's editorial board and masthead information.
Topics
View Full Paper
Ask AI
Bookmark
Share